News
Drug and biotech news
Last checked: Nov 20, 2026Source: BioPharma Dive, STAT (pharma), FDA press releases, FDA MedWatch, Drugs@FDA (new approvals), openFDA (Class I recalls)
14 stories
Tagged Oncology from the headline and teaser, so some stories may be missed or misfiled.
- Trade pressSTAT (pharma)Nov 20, 2026STAT+: Pharmalittle: We're reading about Sanofi eyeing Insmed, AI speeding drug development, and more
Sanofi weighs an Insmed takeover, the FDA slams J&J over misleading bladder cancer drug claims, and more pharma news:
- Trade pressSTAT (pharma)Nov 20, 2026STAT+: Early results for Alterome's KRAS drug for pancreas, lung and colon cancer arrive
Alterome presented preliminary Phase 1 results of its drug “selectively” targeting a range of KRAS mutations — drivers of cancers in the pancreas, lung and colon:
- Trade pressBioPharma DiveNov 20, 2026Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
Wall Street analysts rushed to Celldex's defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva's research chief accepted a new job.
- Trade pressSTAT (pharma)Nov 18, 2026STAT+: FDA discloses reasons for rejecting Summit drug
The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:
- Trade pressBioPharma DiveNov 17, 2026Roche breast cancer pill cleared by FDA
Wilserdly's U.S. approval is seen by analysts as a "key first step" in an important launch for Roche, which has claimed the drug could become its top-selling product.
- Trade pressSTAT (pharma)Nov 17, 2026STAT+: Pharmalittle: We're reading about a Roche breast cancer pill, obesity drugs in children, and more
The FDA approved a breast cancer drug from Roche, teeing up the launch of what the company has said could become its top-selling product
- Trade pressSTAT (pharma)Nov 16, 2026STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
The FDA approved a new breast cancer drug from Roche, teeing up the launch of a medicine the company has said could become its top-selling product ever.
- FDA approvalDrugs@FDANov 10, 2026FDA novel drug approval: Pimjetmi (Pimicotinib), Emd Serono
To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity
- FDAFDA press releasesNov 5, 2026FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell...
- FDAFDA press releasesOct 19, 2026FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common...
- FDA approvalDrugs@FDAOct 19, 2026FDA new use approved: Jemperli (Dostarlimab-Gxly), Glaxosmithkline
Efficacy supplement 15. Priority review.
- FDA approvalDrugs@FDAOct 16, 2026FDA new use approved: Ayvakit (Avapritinib), Blueprint Medicines
Efficacy supplement 21. Orphan.
- FDAFDA press releasesOct 14, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
- FDA approvalDrugs@FDAOct 7, 2026FDA new use approved: Tukysa (Tucatinib), Seagen
Efficacy supplement 10. Orphan.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.